{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:19:10Z","timestamp":1782271150842,"version":"3.54.5"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Basic Res Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i), a new drug class initially designed and approved for treatment of diabetes mellitus, have been shown to exert pleiotropic metabolic and direct cardioprotective and nephroprotective effects that extend beyond their glucose-lowering action. These properties prompted their use in two frequently intertwined conditions, heart failure and chronic kidney disease. Their unique mechanism of action makes SGLT2i an attractive option also to lower the rate of cardiac events and improve overall survival of oncological patients with preexisting cardiovascular risk and\/or candidate to receive cardiotoxic therapies. This review will cover biological foundations and clinical evidence for SGLT2i modulating myocardial function and metabolism, with a focus on their possible use as cardioprotective agents in the cardio-oncology settings. Furthermore, we will explore recently emerged SGLT2i effects on hematopoiesis and immune system, carrying the potential of attenuating tumor growth and chemotherapy-induced cytopenias.<\/jats:p>","DOI":"10.1007\/s00395-024-01059-9","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T11:02:25Z","timestamp":1719486145000},"page":"241-262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Sodium\u2013glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond"],"prefix":"10.1007","volume":"120","author":[{"given":"Massimiliano","family":"Camilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Viscovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Lamendola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Tinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Teofili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hohaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano Antonio","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ferdinandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Crea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Minotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"1059_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/J.JACCAO.2023.03.011","volume":"5","author":"H Abdel-Qadir","year":"2023","unstructured":"Abdel-Qadir H, Carrasco R, Austin PC, Chen Y, Zhou L, Fang J, Su HMH, Lega IC, Kaul P, Neilan TG, Thavendiranathan P (2023) The association of sodium\u2013glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer. JACC CardioOncol 5:318\u2013328. https:\/\/doi.org\/10.1016\/J.JACCAO.2023.03.011","journal-title":"JACC CardioOncol"},{"key":"1059_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/J.CRITREVONC.2019.102837","author":"H Abdel-Razeq","year":"2020","unstructured":"Abdel-Razeq H, Hashem H (2020) Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. Crit Rev Oncol Hematol. https:\/\/doi.org\/10.1016\/J.CRITREVONC.2019.102837","journal-title":"Crit Rev Oncol Hematol"},{"key":"1059_CR3","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/J.JACEP.2023.06.008","volume":"9","author":"MR Abu-Qaoud","year":"2023","unstructured":"Abu-Qaoud MR, Kumar A, Tarun T, Abraham S, Ahmad J, Khadke S, Husami R, Kulbak G, Sahoo S, Januzzi JL, Neilan TG, Baron SJ, Martin D, Nohria A, Reynolds MR, Kosiborod M, Dani SS, Ganatra S (2023) Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type 2 diabetes. JACC Clin Electrophysiol 9:2109\u20132118. https:\/\/doi.org\/10.1016\/J.JACEP.2023.06.008","journal-title":"JACC Clin Electrophysiol"},{"key":"1059_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/S13045-019-0779-5","author":"A Akinleye","year":"2019","unstructured":"Akinleye A, Rasool Z (2019) Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. https:\/\/doi.org\/10.1186\/S13045-019-0779-5","journal-title":"J Hematol Oncol"},{"key":"1059_CR5","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2337\/DB20-1045","volume":"70","author":"M Albiero","year":"2021","unstructured":"Albiero M, Tedesco S, Amendolagine FI, D\u2019anna M, Migliozzi L, Zuccolotto G, Rosato A, Cappellari R, Avogaro A, Fadini GP (2021) Inhibition of SGLT2 rescues bone marrow cell traffic for vascular repair: role of glucose control and ketogenesis. Diabetes 70:1767\u20131779. https:\/\/doi.org\/10.2337\/DB20-1045","journal-title":"Diabetes"},{"key":"1059_CR6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMOA2107038\/SUPPL_FILE\/NEJMOA2107038_DATA-SHARING.PDF","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, Brunner-La Rocca H-P, Choi D-J, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pi\u00f1a IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMOA2107038\/SUPPL_FILE\/NEJMOA2107038_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"key":"1059_CR7","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.1161\/RES.0000000000000473","volume":"129","author":"A Asnani","year":"2021","unstructured":"Asnani A, Moslehi JJ, Adhikari BB, Baik AH, Beyer AM, De Boer RA, Ghigo A, Grumbach IM, Jain S, Zhu H (2021) Preclinical models of cancer therapy-associated cardiovascular toxicity: a scientific statement from the American Heart Association. Circ Res 129:E21\u2013E34. https:\/\/doi.org\/10.1161\/RES.0000000000000473","journal-title":"Circ Res"},{"key":"1059_CR8","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/DC21-S009","volume":"44","author":"AD Association","year":"2021","unstructured":"Association AD (2021) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142021. Diabetes Care 44:S111\u2013S124. https:\/\/doi.org\/10.2337\/DC21-S009","journal-title":"Diabetes Care"},{"key":"1059_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/J.CTRV.2018.07.009","volume":"70","author":"MB Atkins","year":"2018","unstructured":"Atkins MB, Tannir NM (2018) Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev 70:127\u2013137. https:\/\/doi.org\/10.1016\/J.CTRV.2018.07.009","journal-title":"Cancer Treat Rev"},{"key":"1059_CR10","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","volume":"133","author":"G Aubert","year":"2016","unstructured":"Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, Koves T, Gardell SJ, Kr\u00fcger M, Hoppel CL, Lewandowski ED, Crawford PA, Muoio DM, Kelly DP (2016) The Failing Heart Relies on Ketone Bodies as a Fuel. Circulation 133:698\u2013705. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.017355","journal-title":"Circulation"},{"key":"1059_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCHF.2023.08.026","author":"V Avula","year":"2023","unstructured":"Avula V, Sharma G, Kosiborod MN, Vaduganathan M, Neilan TG, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke S, Yang EH, Ky B, Lenihan D, Nohria A, Dani SS, Ganatra S (2023) SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction. JACC Heart Fail. https:\/\/doi.org\/10.1016\/J.JCHF.2023.08.026","journal-title":"JACC Heart Fail"},{"key":"1059_CR12","doi-asserted-by":"publisher","unstructured":"Ay C, Grilz E, Nopp S, Moik F, K\u00f6nigsbr\u00fcgge O, Klimek P, Thurner S, Posch F, Pabinger I (2022) Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study. Res Pract Thromb Haemost 7. https:\/\/doi.org\/10.1016\/J.RPTH.2022.100026","DOI":"10.1016\/J.RPTH.2022.100026"},{"key":"1059_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1056\/NEJMOA1504720","volume":"373","author":"Z Bernard","year":"2015","unstructured":"Bernard Z, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broed UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:17\u201318. https:\/\/doi.org\/10.1056\/NEJMOA1504720","journal-title":"N Engl J Med"},{"key":"1059_CR14","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/S00125-016-4134-X\/FIGURES\/2","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, W\u00fcst RCI, Fiolet JWT, Stienen GJM, Coronel R, Zuurbier CJ (2017) Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits. Diabetologia 60:568\u2013573. https:\/\/doi.org\/10.1007\/S00125-016-4134-X\/FIGURES\/2","journal-title":"Diabetologia"},{"key":"1059_CR15","doi-asserted-by":"publisher","unstructured":"Bhagat A, Shrestha P, Kleinerman ES (2022) The Innate Immune System in Cardiovascular Diseases and Its Role in Doxorubicin-Induced Cardiotoxicity. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/IJMS232314649","DOI":"10.3390\/IJMS232314649"},{"key":"1059_CR16","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/BLOODADVANCES.2018030387","volume":"3","author":"J Bohlius","year":"2019","unstructured":"Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, Mountzios G, Peswani N, Porter L, Tanaka TN, Trifiro G, Yang H, Lazo-Langner A (2019) Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update. Blood Adv 3:1197\u20131210. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2018030387","journal-title":"Blood Adv"},{"key":"1059_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/J.DIABET.2018.09.005","volume":"44","author":"F Bonnet","year":"2018","unstructured":"Bonnet F, Scheen AJ (2018) Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab 44:457\u2013464. https:\/\/doi.org\/10.1016\/J.DIABET.2018.09.005","journal-title":"Diabetes Metab"},{"key":"1059_CR18","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.21873\/ANTICANRES.15348","volume":"41","author":"W Bouleftour","year":"2021","unstructured":"Bouleftour W, Mery B, Rowinski E, Rivier C, Daguenet E, Magne N (2021) Cardio-Oncology Preclinical Models: A Comprehensive Review. Anticancer Res 41:5355\u20135364. https:\/\/doi.org\/10.21873\/ANTICANRES.15348","journal-title":"Anticancer Res"},{"key":"1059_CR19","doi-asserted-by":"publisher","first-page":"E74","DOI":"10.1093\/EHJCVP\/PVAB034","volume":"7","author":"M Camilli","year":"2021","unstructured":"Camilli M, Lombardi M, Chiabrando JG, Del Buono MG, Montone RA, Biondi-Zoccai G, Crea F, Minotti G (2021) Efficacy of sodium\u2013glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: an updated meta-analysis. Eur Heart J Cardiovasc Pharmacother 7:E74\u2013E76. https:\/\/doi.org\/10.1093\/EHJCVP\/PVAB034","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1059_CR20","doi-asserted-by":"publisher","first-page":"E199","DOI":"10.1097\/MJT.0000000000001452","volume":"29","author":"M Camilli","year":"2022","unstructured":"Camilli M, Lombardi M, Chiabrando JG, Zito A, Del Buono MG, Vergallo R, Aspromonte N, Lombardo A, Montone RA, Niccoli G, Biondi-Zoccai G, Crea F, Minotti G (2022) Sodium\u2013glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients with Heart Failure: Evidence from a Meta-Analysis of Randomized Trials. Am J Ther 29:E199\u2013E204. https:\/\/doi.org\/10.1097\/MJT.0000000000001452","journal-title":"Am J Ther"},{"key":"1059_CR21","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/J.JACC.2018.01.085","volume":"71","author":"MA Cavender","year":"2018","unstructured":"Cavender MA, Norhammar A, Birkeland KI, J\u00f8rgensen ME, Wilding JP, Khunti K, Fu AZ, Bodeg\u00e5rd J, Blak BT, Wittbrodt ET, Thuresson M, Fenici P, Hammar N, Kosiborod M, Holl RW, Chen H, Scheerer MF, Surmont F, Nahrebne K, Gulseth HL, Carstensen B, Bollow E, Garc\u00eda Rodr\u00edguez LA, Cea Soriano L, Cantero OF, Thiel E, Murphy B (2018) SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. J Am Coll Cardiol 71:2497\u20132506. https:\/\/doi.org\/10.1016\/J.JACC.2018.01.085","journal-title":"J Am Coll Cardiol"},{"key":"1059_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/S13300-010-0006-4\/FIGURES\/28","volume":"1","author":"J Chen","year":"2010","unstructured":"Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN (2010) Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Therapy 1:57\u201392. https:\/\/doi.org\/10.1007\/S13300-010-0006-4\/FIGURES\/28","journal-title":"Diabetes Therapy"},{"key":"1059_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/J.IJCARD.2016.06.009","volume":"219","author":"WL Cheng","year":"2016","unstructured":"Cheng WL, Kao YH, Chen SA, Chen YJ (2016) Pathophysiology of cancer therapy-provoked atrial fibrillation. Int J Cardiol 219:186\u2013194. https:\/\/doi.org\/10.1016\/J.IJCARD.2016.06.009","journal-title":"Int J Cardiol"},{"key":"1059_CR24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/HEARTJNL-2022-321545","volume":"109","author":"CH Chiang","year":"2023","unstructured":"Chiang CH, Chiang CH, Chiang CH, Ma KSK, Peng CY, Hsia YP, Horng CS, Chen CY, Chang YC, See XY, Chen YJ, Wang SS, Suero-Abreu GA, Peterson LR, Thavendiranathan P, Armand P, Peng CM, Shiah HS, Neilan TG (2023) Impact of sodium\u2013glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. Heart 109:470\u2013477. https:\/\/doi.org\/10.1136\/HEARTJNL-2022-321545","journal-title":"Heart"},{"key":"1059_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/S41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M (2020) SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol 17:761\u2013772. https:\/\/doi.org\/10.1038\/S41569-020-0406-8","journal-title":"Nat Rev Cardiol"},{"key":"1059_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2023.114907","volume":"164","author":"MS Dabour","year":"2023","unstructured":"Dabour MS, Abdelgawad IY, Grant MKO, El-Sawaf ES, Zordoky BN (2023) Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway. Biomed Pharmacother 164:114907. https:\/\/doi.org\/10.1016\/J.BIOPHA.2023.114907","journal-title":"Biomed Pharmacother"},{"key":"1059_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154754","author":"L Ding","year":"2023","unstructured":"Ding L, Chen X, Zhang W, Dai X, Guo H, Pan X, Xu Y, Feng J, Yuan M, Gao X, Wang J, Xu X, Li S, Wu H, Cao J, He Q, Yang B (2023) Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI154754","journal-title":"J Clin Invest"},{"key":"1059_CR28","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1126\/SCIENCE.1169956\/SUPPL_FILE\/DIOUM_SOM.PDF","volume":"324","author":"EM Dioum","year":"2009","unstructured":"Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD, Garcia JA (2009) Regulation of Hypoxia-Inducible Factor 2\u03b1 Signaling by the Stress-Responsive Deacetylase Sirtuin 1. Science (1979) 324:1289\u20131293. https:\/\/doi.org\/10.1126\/SCIENCE.1169956\/SUPPL_FILE\/DIOUM_SOM.PDF","journal-title":"Science (1979)"},{"key":"1059_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14235811","author":"M Dutka","year":"2022","unstructured":"Dutka M, Bobi\u0144ski R, Francuz T, Garczorz W, Zimmer K, Ilczak T, \u0106wiertnia M, Hajduga MB (2022) SGLT-2 inhibitors in cancer treatment-mechanisms of action and emerging new perspectives. Cancers (Basel). https:\/\/doi.org\/10.3390\/CANCERS14235811","journal-title":"Cancers (Basel)"},{"key":"1059_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/J.DSX.2022.102702","author":"P Ekanayake","year":"2023","unstructured":"Ekanayake P, Mudaliar S (2023) Increase in hematocrit with SGLT-2 inhibitors\u2014hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia? Diabetes Metab Syndr. https:\/\/doi.org\/10.1016\/J.DSX.2022.102702","journal-title":"Diabetes Metab Syndr"},{"key":"1059_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2023.107171","volume":"150","author":"A Faggiano","year":"2023","unstructured":"Faggiano A, Gherbesi E, Cardinale D, Vicenzi M, Carugo S (2023) SGLT2-i prevent left ventricular dysfunction induced by anthracycline in mouse model: a systematic-review and meta-analysis. Vascul Pharmacol 150:107171. https:\/\/doi.org\/10.1016\/j.vph.2023.107171","journal-title":"Vascul Pharmacol"},{"key":"1059_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/S41569-022-00735-4","volume":"20","author":"X Fang","year":"2023","unstructured":"Fang X, Ardehali H, Min J, Wang F (2023) The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat Rev Cardiol 20:7\u201323. https:\/\/doi.org\/10.1038\/S41569-022-00735-4","journal-title":"Nat Rev Cardiol"},{"key":"1059_CR33","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1016\/J.JACC.2018.02.078","volume":"71","author":"ME Farkouh","year":"2018","unstructured":"Farkouh ME, Verma S (2018) Prevention of heart failure with SGLT-2 inhibition: insights from CVD-real. J Am Coll Cardiol 71:2507\u20132510. https:\/\/doi.org\/10.1016\/J.JACC.2018.02.078","journal-title":"J Am Coll Cardiol"},{"key":"1059_CR34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/EJHF.2079","volume":"23","author":"D Farmakis","year":"2021","unstructured":"Farmakis D, Filippatos G (2021) Arrhythmias in cancer: rhythm is gonna get you! Eur J Heart Fail 23:154\u2013156. https:\/\/doi.org\/10.1002\/EJHF.2079","journal-title":"Eur J Heart Fail"},{"key":"1059_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/J.1600-065X.2010.00923.X","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219\u2013242. https:\/\/doi.org\/10.1111\/J.1600-065X.2010.00923.X","journal-title":"Immunol Rev"},{"issue":"12","key":"1059_CR36","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/ncb3064","volume":"16","author":"JP Friedmann Angeli","year":"2014","unstructured":"Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch A, Eggenhofer E, Basavarajappa D, R\u00e5dmark O, Kobayashi S, Seibt T, Beck H, Neff F, Esposito I, Wanke R, F\u00f6rster H, Yefremova O, Heinrichmeyer M, Bornkamm GW, Geissler EK, Thomas SB, Stockwell BR, Odonnell VB, Kagan VE, Schick JA, Conrad M (2014) Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 16(12):1180\u20131191. https:\/\/doi.org\/10.1038\/ncb3064","journal-title":"Nat Cell Biol"},{"key":"1059_CR37","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/EJHF.2735","volume":"25","author":"C Fuchs Andersen","year":"2023","unstructured":"Fuchs Andersen C, Omar M, Glenth\u00f8j A, El Fassi D, M\u00f8ller HJ, Lindholm Kurtzhals JA, Styrishave B, Kistorp C, Tuxen C, Poulsen MK, Faber J, K\u00f8ber L, Gustafsson F, M\u00f8ller JE, Schou M, Jensen J (2023) Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial. Eur J Heart Fail 25:226\u2013234. https:\/\/doi.org\/10.1002\/EJHF.2735","journal-title":"Eur J Heart Fail"},{"key":"1059_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/FPUBH.2023.1264056","author":"M Fujiwara","year":"2023","unstructured":"Fujiwara M, Shimizu M, Okano T, Maejima Y, Shimomura K (2023) Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium\u2013glucose transporter 2 inhibitor: a case report and systematic review. Front Public Health. https:\/\/doi.org\/10.3389\/FPUBH.2023.1264056","journal-title":"Front Public Health"},{"key":"1059_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00018-023-04922-5\/FIGURES\/6","volume":"80","author":"J Gambardella","year":"2023","unstructured":"Gambardella J, Santulli G, Fiordelisi A, Cerasuolo FA, Wang X, Prevete N, Sommella E, Avvisato R, Buonaiuto A, Altobelli GG, Rinaldi L, Chiuso F, Feliciello A, Dal Piaz F, Campiglia P, Ciccarelli M, Morisco C, Sadoshima J, Iaccarino G, Sorriento D (2023) Infiltrating macrophages amplify doxorubicin-induced cardiac damage: role of catecholamines. Cell Mol Life Sci 80:1\u201314. https:\/\/doi.org\/10.1007\/S00018-023-04922-5\/FIGURES\/6","journal-title":"Cell Mol Life Sci"},{"key":"1059_CR40","first-page":"13","volume":"33","author":"S Ganapathy-Kanniappan","year":"2013","unstructured":"Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF (2013) Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting. Anticancer Res 33:13\u201320","journal-title":"Anticancer Res"},{"key":"1059_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/AJH.26933","author":"N Gangat","year":"2023","unstructured":"Gangat N, Abdallah M, Szuber N, Saliba A, Alkhateeb H, Al-Kali A, Begna KH, Pardanani A, Tefferi A (2023) Sodium\u2013glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases. Am J Hematol. https:\/\/doi.org\/10.1002\/AJH.26933","journal-title":"Am J Hematol"},{"key":"1059_CR42","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/BLOOD.2021013996","volume":"138","author":"N Gangat","year":"2021","unstructured":"Gangat N, Szuber N, Alkhateeb H, Al-Kali A, Pardanani A, Tefferi A (2021) JAK2 wild-type erythrocytosis associated with sodium\u2013glucose cotransporter 2 inhibitor therapy. Blood 138:2886\u20132889. https:\/\/doi.org\/10.1182\/BLOOD.2021013996","journal-title":"Blood"},{"key":"1059_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/FCVM.2022.1011429","author":"J Gao","year":"2022","unstructured":"Gao J, Xue G, Zhan G, Wang X, Li J, Yang X, Xia Y (2022) Benefits of SGLT2 inhibitors in arrhythmias. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/FCVM.2022.1011429","journal-title":"Front Cardiovasc Med"},{"key":"1059_CR44","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.molcel.2015.06.011","volume":"59","author":"M Gao","year":"2015","unstructured":"Gao M, Monian P, Quadri N, Ramasamy R, Jiang X (2015) Glutaminolysis and transferrin regulate ferroptosis. Mol Cell 59:298\u2013308. https:\/\/doi.org\/10.1016\/j.molcel.2015.06.011","journal-title":"Mol Cell"},{"key":"1059_CR45","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1210\/CLINEM\/DGAA057","volume":"105","author":"H Ghanim","year":"2020","unstructured":"Ghanim H, Abuaysheh S, Hejna J, Green K, Batra M, Makdissi A, Chaudhuri A, Dandona P (2020) Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab 105:e1056\u2013e1063. https:\/\/doi.org\/10.1210\/CLINEM\/DGAA057","journal-title":"J Clin Endocrinol Metab"},{"key":"1059_CR46","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/J.JCHF.2022.03.006","volume":"10","author":"CA Gongora","year":"2022","unstructured":"Gongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, Zafar A, Gong J, Zlotoff DA, Gilman HK, Hartmann SE, Sama S, Nikolaidou S, Suero-Abreu GA, Jacobsen E, Abramson JS, Hochberg E, Barnes J, Armand P, Thavendiranathan P, Nohria A, Neilan TG (2022) Sodium\u2013glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail 10:559\u2013567. https:\/\/doi.org\/10.1016\/J.JCHF.2022.03.006","journal-title":"JACC Heart Fail"},{"key":"1059_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12933-016-0489-Z\/FIGURES\/7","volume":"16","author":"J Habibi","year":"2017","unstructured":"Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, DeMarco VG (2017) Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol 16:1\u201315. https:\/\/doi.org\/10.1186\/S12933-016-0489-Z\/FIGURES\/7","journal-title":"Cardiovasc Diabetol"},{"key":"1059_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/FCVM.2021.590768","author":"LA Hajjar","year":"2021","unstructured":"Hajjar LA, Fonseca SMR, Machado TIV (2021) Atrial fibrillation and cancer. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/FCVM.2021.590768","journal-title":"Front Cardiovasc Med"},{"key":"1059_CR49","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L (2020) PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10:727\u2013742","journal-title":"Am J Cancer Res"},{"key":"1059_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0274519","author":"M Hendryx","year":"2022","unstructured":"Hendryx M, Dong Y, Ndeke JM, Luo J (2022) Sodium\u2013glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis. PLoS ONE. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0274519","journal-title":"PLoS ONE"},{"key":"1059_CR51","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/J.CMET.2019.08.015","volume":"30","author":"DA Hess","year":"2019","unstructured":"Hess DA, Terenzi DC, Trac JZ, Quan A, Mason T, Al-Omran M, Bhatt DL, Dhingra N, Rotstein OD, Leiter LA, Zinman B, Sabongui S, Yan AT, Teoh H, Mazer CD, Connelly KA, Verma S (2019) SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus. Cell Metab 30:609\u2013613. https:\/\/doi.org\/10.1016\/J.CMET.2019.08.015","journal-title":"Cell Metab"},{"key":"1059_CR52","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1093\/cvr\/cvad111","volume":"119","author":"G Heusch","year":"2023","unstructured":"Heusch G (2023) Cardioprotection in cardio-oncology: a case for concern? Cardiovasc Res 119:e144\u2013e145. https:\/\/doi.org\/10.1093\/cvr\/cvad111","journal-title":"Cardiovasc Res"},{"key":"1059_CR53","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.medj.2023.12.007","volume":"5","author":"G Heusch","year":"2024","unstructured":"Heusch G (2024) Myocardial ischemia\/reperfusion: translational pathophysiology of ischemic heart disease. Med (N Y) 5:10\u201331. https:\/\/doi.org\/10.1016\/j.medj.2023.12.007","journal-title":"Med (N Y)"},{"key":"1059_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102894","volume":"67","author":"G Heusch","year":"2023","unstructured":"Heusch G, Andreadou I, Bell R, Bertero E, Botker H-E, Davidson SM, Downey J, Eaton P, Ferdinandy P, Gersh BJ, Giacca M, Hausenloy DJ, Ibanez B, Krieg T, Maack C, Schulz R, Sellke F, Shah AM, Thiele H, Yellon DM, Di Lisa F (2023) Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection. Redox Biol 67:102894. https:\/\/doi.org\/10.1016\/j.redox.2023.102894","journal-title":"Redox Biol"},{"key":"1059_CR55","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1161\/CIRCHEARTFAILURE.113.001020","volume":"7","author":"U Hofmann","year":"2014","unstructured":"Hofmann U, Knorr S, Vogel B, Weirather J, Frey A, Ertl G, Frantz S (2014) Interleukin-13 deficiency aggravates healing and remodeling in male mice after experimental myocardial infarction. Circ Heart Fail 7:822\u2013830. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.113.001020","journal-title":"Circ Heart Fail"},{"key":"1059_CR56","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1006\/MGME.2000.3043","volume":"71","author":"MS Horenstein","year":"2000","unstructured":"Horenstein MS, Vander Heide RS, L\u2019Ecuyer TJ (2000) Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab 71:436\u2013444. https:\/\/doi.org\/10.1006\/MGME.2000.3043","journal-title":"Mol Genet Metab"},{"key":"1059_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBAMCR.2020.118711","author":"SK Jahn","year":"2020","unstructured":"Jahn SK, Hennicke T, Kassack MU, Drews L, Reichert AS, Fritz G (2020) Distinct influence of the anthracycline derivative doxorubicin on the differentiation efficacy of mESC-derived endothelial progenitor cells. Biochim Biophys Acta Mol Cell Res. https:\/\/doi.org\/10.1016\/J.BBAMCR.2020.118711","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1059_CR58","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/J.IJCARD.2014.09.148","volume":"177","author":"WMC Jong","year":"2014","unstructured":"Jong WMC, Leemans JC, Weber NC, Juffermans NP, Schultz MJ, Hollmann MW, Zuurbier CJ (2014) Nlrp3 plays no role in acute cardiac infarction due to low cardiac expression. Int J Cardiol 177:41\u201343. https:\/\/doi.org\/10.1016\/J.IJCARD.2014.09.148","journal-title":"Int J Cardiol"},{"key":"1059_CR59","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","volume":"24","author":"RW Joseph","year":"2018","unstructured":"Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, De Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC (2018) Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin Cancer Res 24:4960\u20134967. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2386","journal-title":"Clin Cancer Res"},{"key":"1059_CR60","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/IJC.31193","volume":"142","author":"K Kaji","year":"2018","unstructured":"Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kawaratani H, Kitade M, Moriya K, Namisaki T, Yoshiji H (2018) Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer 142:1712\u20131722. https:\/\/doi.org\/10.1002\/IJC.31193","journal-title":"Int J Cancer"},{"key":"1059_CR61","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.3390\/IJMS20133328","volume":"20","author":"N Kelley","year":"2019","unstructured":"Kelley N, Jeltema D, Duan Y, He Y (2019) The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci 20:3328. https:\/\/doi.org\/10.3390\/IJMS20133328","journal-title":"Int J Mol Sci"},{"key":"1059_CR62","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/CCM.0000000000003555","volume":"47","author":"EM Kenny","year":"2019","unstructured":"Kenny EM, Fidan E, Yang Q, Anthonymuthu TS, New LA, Meyer EA, Wang H, Kochanek PM, Dixon CE, Kagan VE, Bayir H (2019) Ferroptosis contributes to neuronal death and functional outcome after traumatic brain injury\u2217. Crit Care Med 47:410\u2013418. https:\/\/doi.org\/10.1097\/CCM.0000000000003555","journal-title":"Crit Care Med"},{"key":"1059_CR63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/J.1752-8062.2008.00090.X","volume":"2","author":"R Kerkela","year":"2009","unstructured":"Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF, Beahm C, Chen MH, Force T (2009) Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2:15\u201325. https:\/\/doi.org\/10.1111\/J.1752-8062.2008.00090.X","journal-title":"Clin Transl Sci"},{"key":"1059_CR64","doi-asserted-by":"publisher","first-page":"E77","DOI":"10.1161\/ATVBAHA.120.313584","volume":"41","author":"MK Khoury","year":"2021","unstructured":"Khoury MK, Yang H, Liu B (2021) Macrophage biology in cardiovascular diseases. Arterioscler Thromb Vasc Biol 41:E77\u2013E81. https:\/\/doi.org\/10.1161\/ATVBAHA.120.313584","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1059_CR65","doi-asserted-by":"publisher","DOI":"10.1007\/S11912-020-00925-8","author":"A Khunger","year":"2020","unstructured":"Khunger A, Battel L, Wadhawan A, More A, Kapoor A, Agrawal N (2020) New insights into mechanisms of immune checkpoint inhibitor-induced cardiovascular toxicity. Curr Oncol Rep. https:\/\/doi.org\/10.1007\/S11912-020-00925-8","journal-title":"Curr Oncol Rep"},{"key":"1059_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, Rim JH, Hwang I, Lee CJ, Lee M, Oh CM, Jeon JY, Gee HY, Kim JH, Lee BW, Kang ES, Cha BS, Lee MS, Yu JW, Cho JW, Kim JS, Lee YH (2020) SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun 11:1\u201311. https:\/\/doi.org\/10.1038\/s41467-020-15983-6","journal-title":"Nat Commun"},{"key":"1059_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/S40425-016-0117-1","author":"VH Koelzer","year":"2016","unstructured":"Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, Voegeli M, Cathomas G, Zippelius A, Mertz KD (2016) Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer. https:\/\/doi.org\/10.1186\/S40425-016-0117-1","journal-title":"J Immunother Cancer"},{"key":"1059_CR68","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.3390\/NU15102294","volume":"15","author":"D Kounatidis","year":"2023","unstructured":"Kounatidis D, Vallianou N, Evangelopoulos A, Vlahodimitris I, Grivakou E, Kotsi E, Dimitriou K, Skourtis A, Mourouzis I (2023) SGLT-2 Inhibitors and the inflammasome: what\u2019s next in the 21st century? Nutrients 15:2294. https:\/\/doi.org\/10.3390\/NU15102294","journal-title":"Nutrients"},{"key":"1059_CR69","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.12659\/MSM.902530","volume":"23","author":"H Kuang","year":"2017","unstructured":"Kuang H, Liao L, Chen H, Kang Q, Shu X, Wang Y (2017) Therapeutic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma. Med Sci Monit 23:3737\u20133745. https:\/\/doi.org\/10.12659\/MSM.902530","journal-title":"Med Sci Monit"},{"key":"1059_CR70","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/S11154-021-09675-9","volume":"22","author":"KTK Lau","year":"2021","unstructured":"Lau KTK, Ng L, Wong JWH, Loong HHF, Chan WWL, Lee CH, Wong CKH (2021) Repurposing sodium\u2013glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment\u2014a review. Rev Endocr Metab Disord 22:1121\u20131136. https:\/\/doi.org\/10.1007\/S11154-021-09675-9","journal-title":"Rev Endocr Metab Disord"},{"key":"1059_CR71","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.2337\/DC18-1421","volume":"41","author":"KM Lauritsen","year":"2018","unstructured":"Lauritsen KM, S\u00f8ndergaard E, Svart M, M\u00f8ller N, Gormsen LC (2018) Ketone body infusion increases circulating erythropoietin and bone marrow glucose uptake. Diabetes Care 41:e152\u2013e154. https:\/\/doi.org\/10.2337\/DC18-1421","journal-title":"Diabetes Care"},{"key":"1059_CR72","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0558","author":"KM Lauritsen","year":"2022","unstructured":"Lauritsen KM, Voigt JH, Pedersen SB, Hansen TK, M\u00f8ller N, Jessen N, Gormsen LC, S\u00f8ndergaard E (2022) Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes. Endocr Connect. https:\/\/doi.org\/10.1530\/EC-21-0558","journal-title":"Endocr Connect"},{"key":"1059_CR73","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/J.JACC.2018.08.2149","volume":"72","author":"KJ Lavine","year":"2018","unstructured":"Lavine KJ, Pinto AR, Epelman S, Kopecky BJ, Clemente-Casares X, Godwin J, Rosenthal N, Kovacic JC (2018) The macrophage in cardiac homeostasis and disease: JACC macrophage in CVD series (Part 4). J Am Coll Cardiol 72:2213\u20132230. https:\/\/doi.org\/10.1016\/J.JACC.2018.08.2149","journal-title":"J Am Coll Cardiol"},{"key":"1059_CR74","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9944880","author":"N Lee","year":"2021","unstructured":"Lee N, Heo YJ, Choi SE, Jeon JY, Han SJ, Kim DJ, Kang Y, Lee KW, Kim HJ (2021) Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK\/NF-\u03baB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways. J Immunol Res. https:\/\/doi.org\/10.1155\/2021\/9944880","journal-title":"J Immunol Res"},{"key":"1059_CR75","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3390\/IJMS20071680","volume":"20","author":"TI Lee","year":"2019","unstructured":"Lee TI, Chen YC, Lin YK, Chung CC, Lu YY, Kao YH, Chen YJ (2019) Empagliflozin attenuates myocardial sodium and calcium dysregulation and reverses cardiac remodeling in streptozotocin-induced diabetic rats. Int J Mol Sci 20:1680. https:\/\/doi.org\/10.3390\/IJMS20071680","journal-title":"Int J Mol Sci"},{"key":"1059_CR76","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/J.FREERADBIOMED.2017.01.035","volume":"104","author":"TM Lee","year":"2017","unstructured":"Lee TM, Chang NC, Lin SZ (2017) Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med 104:298\u2013310. https:\/\/doi.org\/10.1016\/J.FREERADBIOMED.2017.01.035","journal-title":"Free Radic Biol Med"},{"key":"1059_CR77","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12933-023-02019-8","volume":"22","author":"J Li","year":"2023","unstructured":"Li J, Yu Y, Sun Y, Yu B, Tan X, Wang B, Lu Y, Wang N (2023) SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a mendelian randomization study. Cardiovasc Diabetol 22:278. https:\/\/doi.org\/10.1186\/s12933-023-02019-8","journal-title":"Cardiovasc Diabetol"},{"key":"1059_CR78","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW (2016) The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 41:211\u2013218. https:\/\/doi.org\/10.1016\/j.tibs.2015.12.001","journal-title":"Trends Biochem Sci"},{"key":"1059_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/S12933-014-0148-1","author":"B Lin","year":"2014","unstructured":"Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma MJ, Nakagawa T, Kusaka H, Kim-Mitsuyama S (2014) Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. https:\/\/doi.org\/10.1186\/S12933-014-0148-1","journal-title":"Cardiovasc Diabetol"},{"key":"1059_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/FCVM.2021.821663","volume":"8","author":"M Lin","year":"2022","unstructured":"Lin M, Xiong W, Wang S, Li Y, Hou C, Li C, Li G (2022) The Research progress of trastuzumab-induced cardiotoxicity in HER-2-positive breast cancer treatment. Front Cardiovasc Med 8:821663. https:\/\/doi.org\/10.3389\/FCVM.2021.821663","journal-title":"Front Cardiovasc Med"},{"key":"1059_CR81","doi-asserted-by":"publisher","first-page":"16836","DOI":"10.1073\/PNAS.1415518111\/SUPPL_FILE\/PNAS.1415518111.SM04.AVI","volume":"111","author":"A Linkermann","year":"2014","unstructured":"Linkermann A, Skouta R, Himmerkus N, Mulay SR, Dewitz C, De Zen F, Prokai A, Zuchtriegel G, Krombach F, Welz PS, Weinlich R, Vanden BT, Vandenabeele P, Pasparakis M, Bleich M, Weinberg JM, Reichel CA, Br\u00e4sen JH, Kunzendorf U, Anders HJ, Stockwell BR, Green DR, Krautwald S (2014) Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci U S A 111:16836\u201316841. https:\/\/doi.org\/10.1073\/PNAS.1415518111\/SUPPL_FILE\/PNAS.1415518111.SM04.AVI","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1059_CR82","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/S12253-015-9946-3","volume":"21","author":"T L\u0151rincz","year":"2015","unstructured":"L\u0151rincz T, Jemnitz K, Kardon T, Mandl J, Szarka A (2015) Ferroptosis is involved in acetaminophen induced cell death. Pathol Oncol Res 21:1115\u20131121. https:\/\/doi.org\/10.1007\/S12253-015-9946-3","journal-title":"Pathol Oncol Res"},{"key":"1059_CR83","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/S00210-022-02243-1\/FIGURES\/9","volume":"395","author":"S Ma","year":"2022","unstructured":"Ma S, He LL, Zhang GR, Zuo QJ, Wang ZL, Zhai JL, Zhang TT, Wang Y, Ma HJ, Guo YF (2022) Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction. Naunyn Schmiedebergs Arch Pharmacol 395:945\u2013962. https:\/\/doi.org\/10.1007\/S00210-022-02243-1\/FIGURES\/9","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1059_CR84","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/S10741-015-9497-4","volume":"20","author":"R Madonna","year":"2015","unstructured":"Madonna R, Cadeddu C, Deidda M, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Spallarossa P, Tocchetti CG, Zito C, Mercuro G (2015) Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a position paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Fail Rev 20:621\u2013631. https:\/\/doi.org\/10.1007\/S10741-015-9497-4","journal-title":"Heart Fail Rev"},{"key":"1059_CR85","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","volume":"25","author":"A Mantovani","year":"2004","unstructured":"Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677\u2013686. https:\/\/doi.org\/10.1016\/j.it.2004.09.015","journal-title":"Trends Immunol"},{"key":"1059_CR86","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","volume":"44","author":"A Mascolo","year":"2021","unstructured":"Mascolo A, Scavone C, Ferrajolo C et al (2021) Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in eudravigilance. Drug Saf 44:957\u2013971","journal-title":"Drug Saf"},{"key":"1059_CR87","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1038\/SJ.ONC.1209603","volume":"25","author":"SP Mathupala","year":"2006","unstructured":"Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer\u2019s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25:4777\u20134786. https:\/\/doi.org\/10.1038\/SJ.ONC.1209603","journal-title":"Oncogene"},{"key":"1059_CR88","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","volume":"141","author":"CD Mazer","year":"2020","unstructured":"Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A, Teoh H, Leiter LA, Zinman B, J\u00fcni P, Zuo F, Mistry N, Thorpe KE, Goldenberg RM, Yan AT, Connelly KA, Verma S (2020) Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation 141:704\u2013707. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044235","journal-title":"Circulation"},{"key":"1059_CR89","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/EURHEARTJ\/EHAB368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Baumbach A, B\u00f6hm M, Burri H, \u010celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gardner RS, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, de Boer RA, Schulze PC, Abdelhamid M, Aboyans V, Adamopoulos S, Anker SD, Arbelo E, Asteggiano R, Bauersachs J, Bayes-Genis A, Borger MA, Budts W, Cikes M, Damman K, Delgado V, Dendale P, Dilaveris P, Drexel H, Ezekowitz J, Falk V, Fauchier L, Filippatos G, Fraser A, Frey N, Gale CP, Gustafsson F, Harris J, Iung B, Janssens S, Jessup M, Konradi A, Kotecha D, Lambrinou E, Lancellotti P, Landmesser U, Leclercq C, Lewis BS, Leyva F, Linhart A, L\u00f8chen ML, Lund LH, Mancini D, Masip J, Milicic D, Mueller C, Nef H, Nielsen JC, Neubeck L, Noutsias M, Petersen SE, Petronio AS, Ponikowski P, Prescott E, Rakisheva A, Richter D, Schlyakhto E, Seferovic P, Senni M, Sitges M, Sousa-Uva M, Tocchetti CG, Touyz R, Tschoepe C, Waltenberger J, Krim M, Hayrapetyan H, Moertl D, Mustafayev I, Kurlianskaya A, Depauw M, Ku\u0161ljugi\u0107 Z, Gatzov P, Agathangelou P, Melenovsk\u00fd V, L\u00f8gstrup BB, Mostafa AM, Uuetoa T, Lassus J, Logeart D, Kipiani Z, Chrysohoou C, Sepp R, Ingimarsd\u00f3ttir IJ, O\u2019Neill J, Gotsman I, Iacoviello M, Bajraktari G, Lunegova O, Kamzola G, Massih TA, Benlamin H, \u017daliaduonyte D, Noppe S, Moore A, Vataman E, Boskovic A, Bennis A, Manintveld OC, Kostovska ES, Gulati G, Straburzy\u0144ska-Migaj E, Silva-Cardoso J, Rimba\u015f RC, Lopatin Y, Foscoli M, Stojkovic S, Goncalvesova E, Fras Z, Segovia J, Lindmark K, Maeder MT, Bsata W, Abid L, Altay H, Voronkov L, Davies C, Abdullaev T, Baigent CN, Antoniou S, Collet JP, Halvorsen S, Koskinas KC (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u20133726. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB368","journal-title":"Eur Heart J"},{"key":"1059_CR90","doi-asserted-by":"publisher","DOI":"10.1093\/EURHEARTJ\/EHAD195","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, de Boer RA, Schulze PC, Arbelo E, Bartunek J, Bauersachs J, Borger MA, Buccheri S, Cerbai E, Donal E, Edelmann F, F\u00e4rber G, Heidecker B, Ibanez B, James S, K\u00f8ber L, Koskinas KC, Masip J, McEvoy JW, Mentz R, Mihaylova B, M\u00f8ller JE, Mullens W, Neubeck L, Nielsen JC, Pasquet AA, Ponikowski P, Prescott E, Rakisheva A, Rocca B, Rossello X, Sade LE, Schaubroeck H, Tessitore E, Tokmakova M, van der Meer P, Van Gelder IC, Van Heetvelde M, Vrints C, Wilhelm M, Witkowski A, Zeppenfeld K, Shuka N, Chettibi M, Hayrapetyan H, Pavo N, Islamli A, Pouleur A-C, Kusljugic Z, Tokmakova M, Milicic D, Christodoulides T, Malek F, K\u00f8ber L, Koriem MAG, P\u00f5der P, Lassus J, Roubille F, Agladze V, Frantz S, Stavrati A, Kosztin A, Ingimarsd\u00f3ttir IJ, Campbell P, Hasin T, Oliva F, Aidargaliyeva N, Bajraktari G, Mirrakhimov E, Kamzola G, El Neihoum AM, Zaliaduonyte D, Moore A, Vataman E, Boskovic A, Alami M, Manintveld O, Kostovska ES, Broch K, Nessler J, Franco F, Popescu BA, Foscoli M, Milosavljevic AS, Goncalvesova E, Fras Z, Gonzalez-Costello J, Lindmark K, Paul M, Oudeh A, Zakhama L, Celik A, Voronkov L, Clark A, Abdullaev T, Prescott E, James S, Arbelo E, Baigent C, Borger MA, Buccheri S, Ibanez B, K\u00f8ber L, Koskinas KC, McEvoy JW, Mihaylova B, Mindham R, Neubeck L, Nielsen JC, Pasquet AA, Rakisheva A, Rocca B, Rossello X, Vaartjes I, Vrints C, Witkowski A, Zeppenfeld K (2023) 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAD195","journal-title":"Eur Heart J"},{"key":"1059_CR91","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMOA1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B\u011blohl\u00e1vek J, B\u00f6hm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Duk\u00e1t A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sj\u00f6strand M, Langkilde A-M (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMOA1911303","journal-title":"N Engl J Med"},{"key":"1059_CR92","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/EHJQCCO\/QCX004","volume":"3","author":"C Melloni","year":"2017","unstructured":"Melloni C, Shrader P, Carver J, Piccini JP, Thomas L, Fonarow GC, Ansell J, Gersh B, Go AS, Hylek E, Herling IM, Mahaffey KW, Yu AF, Peterson ED, Kowey PR (2017) Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes 3:192\u2013197. https:\/\/doi.org\/10.1093\/EHJQCCO\/QCX004","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"1059_CR93","doi-asserted-by":"publisher","first-page":"19725","DOI":"10.1073\/PNAS.1108586108\/SUPPL_FILE\/PNAS.201108586SI.PDF","volume":"108","author":"E Mezzaroma","year":"2011","unstructured":"Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN, Kannan HR, Menna AC, Voelkel NF, Abbate A (2011) The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A 108:19725\u201319730. https:\/\/doi.org\/10.1073\/PNAS.1108586108\/SUPPL_FILE\/PNAS.201108586SI.PDF","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1059_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/J.LFS.2022.121207","volume":"312","author":"J Min","year":"2023","unstructured":"Min J, Wu L, Liu Y, Song G, Deng Q, Jin W, Yu W, Miyesaier A, Pei Z, Ren J (2023) Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis. Life Sci 312:121207. https:\/\/doi.org\/10.1016\/J.LFS.2022.121207","journal-title":"Life Sci"},{"key":"1059_CR95","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/BS.APHA.2022.02.002","volume":"94","author":"G Minotti","year":"2022","unstructured":"Minotti G, Menna P, Camilli M, Salvatorelli E, Levi R (2022) Beyond hypertension: diastolic dysfunction associated with cancer treatment in the era of cardio-oncology. Adv Pharmacol 94:365\u2013409. https:\/\/doi.org\/10.1016\/BS.APHA.2022.02.002","journal-title":"Adv Pharmacol"},{"key":"1059_CR96","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/J.JACCAO.2021.12.002","volume":"4","author":"G Minotti","year":"2022","unstructured":"Minotti G, Reggiardo G, Camilli M, Salvatorelli E, Menna P (2022) From cardiac anthracycline accumulation to real-life risk for early diastolic dysfunction: a translational approach. Cardio Oncology 4:139\u2013140. https:\/\/doi.org\/10.1016\/J.JACCAO.2021.12.002","journal-title":"Cardio Oncology"},{"key":"1059_CR97","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/S12020-016-0943-4","volume":"53","author":"RP Monica Reddy","year":"2016","unstructured":"Monica Reddy RP, Inzucchi SE (2016) SGLT2 inhibitors in the management of type 2 diabetes. Endocrine 53:364\u2013372. https:\/\/doi.org\/10.1007\/S12020-016-0943-4","journal-title":"Endocrine"},{"key":"1059_CR98","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1023\/A:1008498705032","volume":"9","author":"I Moullet","year":"1998","unstructured":"Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard EM, Thieblemont C, Felman P, Coiffier B (1998) Frequency and significance of anemia in non-Hodgkin\u2019s lymphoma patients. Ann Oncol 9:1109\u20131115. https:\/\/doi.org\/10.1023\/A:1008498705032","journal-title":"Ann Oncol"},{"key":"1059_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2022.112864","author":"S Nakachi","year":"2022","unstructured":"Nakachi S, Okamoto S, Tamaki K, Nomura I, Tomihama M, Nishi Y, Fukushima T, Tanaka Y, Morishima S, Imamura M, Maeda S, Tsutsui M, Matsushita M, Masuzaki H (2022) Impact of anti-diabetic sodium\u2013glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans. Biomed Pharmacother. https:\/\/doi.org\/10.1016\/J.BIOPHA.2022.112864","journal-title":"Biomed Pharmacother"},{"key":"1059_CR100","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMOA1611925\/SUPPL_FILE\/NEJMOA1611925_DISCLOSURES.PDF","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657. https:\/\/doi.org\/10.1056\/NEJMOA1611925\/SUPPL_FILE\/NEJMOA1611925_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"key":"1059_CR101","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1089\/ARS.2019.7923","volume":"34","author":"PE Nikolaou","year":"2021","unstructured":"Nikolaou PE, Efentakis P, Abu Qourah F, Femmin\u00f2 S, Makridakis M, Kanaki Z, Varela A, Tsoumani M, Davos CH, Dimitriou CA, Tasouli A, Dimitriadis G, Kostomitsopoulos N, Zuurbier CJ, Vlahou A, Klinakis A, Brizzi MF, Iliodromitis EK, Andreadou I (2021) Chronic empagliflozin treatment reduces myocardial infarct size in nondiabetic mice through STAT-3-mediated protection on microvascular endothelial cells and reduction of oxidative stress. Antioxid Redox Signal 34:551\u2013571. https:\/\/doi.org\/10.1089\/ARS.2019.7923","journal-title":"Antioxid Redox Signal"},{"key":"1059_CR102","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.4070\/KCJ.2019.0180","volume":"49","author":"CM Oh","year":"2019","unstructured":"Oh CM, Cho S, Jang JY, Kim H, Chun S, Choi M, Park S, Ko YG (2019) Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure. Korean Circ J 49:1183\u20131195. https:\/\/doi.org\/10.4070\/KCJ.2019.0180","journal-title":"Korean Circ J"},{"key":"1059_CR103","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/EJHF.2731","volume":"24","author":"M Packer","year":"2022","unstructured":"Packer M (2022) How can sodium\u2013glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron-deficient? Implications for understanding iron homeostasis in heart failure. Eur J Heart Fail 24:2287\u20132296. https:\/\/doi.org\/10.1002\/EJHF.2731","journal-title":"Eur J Heart Fail"},{"key":"1059_CR104","doi-asserted-by":"publisher","DOI":"10.1093\/EURHEARTJ\/EHAD235","author":"M Packer","year":"2023","unstructured":"Packer M (2023) Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium\u2013glucose cotransporter 2 inhibitors. Eur Heart J. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAD235","journal-title":"Eur Heart J"},{"key":"1059_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40170-023-00306-2","volume":"11","author":"LK Park","year":"2023","unstructured":"Park LK, Lim K-H, Volkman J, Abdiannia M, Johnston H, Nigogosyan Z, Siegel MJ, McGill JB, McKee AM, Salam M, Zhang RM, Ma D, Popuri K, Chow VTY, Beg MF, Hawkins WG, Peterson LR (2023) Safety, tolerability, and effectiveness of the sodium\u2013glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study. Cancer Metab 11:1\u201312. https:\/\/doi.org\/10.1186\/S40170-023-00306-2","journal-title":"Cancer Metab"},{"key":"1059_CR106","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/S41419-019-2061-8","volume":"10","author":"TJ Park","year":"2019","unstructured":"Park TJ, Park JH, Lee GS, Lee JY, Shin JH, Kim MW, Kim YS, Kim JY, Oh KJ, Han BS, Kim WK, Ahn Y, Moon JH, Song J, Bae KH, Kim DH, Lee EW, Lee SC (2019) Quantitative proteomic analyses reveal that GPX4 downregulation during myocardial infarction contributes to ferroptosis in cardiomyocytes. Cell Death Dis 10:835. https:\/\/doi.org\/10.1038\/S41419-019-2061-8","journal-title":"Cell Death Dis"},{"key":"1059_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-54224-9","volume":"9","author":"J Pennig","year":"2019","unstructured":"Pennig J, Scherrer P, Gissler MC, Anto-Michel N, Hoppe N, F\u00fcner L, H\u00e4rdtner C, Stachon P, Wolf D, Hilgendorf I, Mullick A, Bode C, Zirlik A, Goldberg IJ, Willecke F (2019) Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice. Sci Rep 9:1\u201312. https:\/\/doi.org\/10.1038\/s41598-019-54224-9","journal-title":"Sci Rep"},{"key":"1059_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/S40959-023-00199-6","author":"MG Perelman","year":"2024","unstructured":"Perelman MG, Brzezinski RY, Waissengrin B, Leshem Y, Bainhoren O, Rubinstein TA, Perelman M, Rozenbaum Z, Havakuk O, Topilsky Y, Banai S, Wolf I, Laufer-Perl M (2024) Sodium\u2013glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors. Cardiooncology. https:\/\/doi.org\/10.1186\/S40959-023-00199-6","journal-title":"Cardiooncology"},{"key":"1059_CR109","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMRA1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMRA1703481","journal-title":"N Engl J Med"},{"key":"1059_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2019.02298","author":"W Qin","year":"2019","unstructured":"Qin W, Hu L, Zhang X, Jiang S, Li J, Zhang Z, Wang X (2019) The diverse function of PD-1\/PD-L pathway beyond cancer. Front Immunol. https:\/\/doi.org\/10.3389\/FIMMU.2019.02298","journal-title":"Front Immunol"},{"key":"1059_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/S12933-021-01346-Y","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A, Paccone A, Altucci L, Conte M, Canale ML, Botti G, Maurea N (2021) The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. https:\/\/doi.org\/10.1186\/S12933-021-01346-Y","journal-title":"Cardiovasc Diabetol"},{"key":"1059_CR112","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/J.JACCAO.2023.09.002","volume":"5","author":"C Quartermaine","year":"2023","unstructured":"Quartermaine C, Ghazi SM, Yasin A, Awan FT, Fradley M, Wiczer T, Kalathoor S, Ferdousi M, Krishan S, Habib A, Shaaban A, Kola-Kehinde O, Kittai AS, Rogers KA, Grever M, Ruz P, Bhat S, Dickerson T, Byrd JC, Woyach J, Addison D (2023) Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 5:570\u2013590. https:\/\/doi.org\/10.1016\/J.JACCAO.2023.09.002","journal-title":"JACC CardioOncol"},{"key":"1059_CR113","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/S43188-023-00204-1","volume":"40","author":"MMM Refaie","year":"2023","unstructured":"Refaie MMM, Shehata S, El-Hussieny M, Fawzy MA, Ahmed NZM, Marey H, Hishmat AM, Alkully T, El RESMA (2023) Molecular mechanism of empagliflozin cardioprotection in 5-fluorouracil (5-FU)-induced cardiotoxicity via modulation of SGLT2 and TNF\u03b1\/TLR\/NF-\u03baB signaling pathway in rats. Toxicol Res 40:139\u2013151. https:\/\/doi.org\/10.1007\/S43188-023-00204-1","journal-title":"Toxicol Res"},{"key":"1059_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/BIOM11111725","author":"A Reis-Mendes","year":"2021","unstructured":"Reis-Mendes A, Padr\u00e3o AI, Duarte JA, Gon\u00e7alves-Monteiro S, Duarte-Ara\u00fajo M, Remi\u00e3o F, Carvalho F, Sousa E, Bastos ML, Costa VM (2021) Role of inflammation and redox status on doxorubicin-induced cardiotoxicity in infant and adult CD-1 male mice. Biomolecules. https:\/\/doi.org\/10.3390\/BIOM11111725","journal-title":"Biomolecules"},{"key":"1059_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2021.664181","author":"C Ren","year":"2021","unstructured":"Ren C, Sun K, Zhang Y, Hu Y, Hu B, Zhao J, He Z, Ding R, Wang W, Liang C (2021) Sodium\u2013glucose cotransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK-mTOR signaling pathway-mediated autophagy. Front Pharmacol. https:\/\/doi.org\/10.3389\/FPHAR.2021.664181","journal-title":"Front Pharmacol"},{"key":"1059_CR116","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/J.EJPHAR.2017.10.043","volume":"818","author":"K Renu","year":"2017","unstructured":"Renu K, Abilash VG, Tirupathi TP, Arunachalam S (2017) Molecular mechanism of doxorubicin-induced cardiomyopathy\u2014an update. Eur J Pharmacol 818:241\u2013253. https:\/\/doi.org\/10.1016\/J.EJPHAR.2017.10.043","journal-title":"Eur J Pharmacol"},{"key":"1059_CR117","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/J.TCM.2012.07.003","volume":"22","author":"C Riehle","year":"2012","unstructured":"Riehle C, Abel ED (2012) PGC-1 proteins and heart failure. Trends Cardiovasc Med 22:98\u2013105. https:\/\/doi.org\/10.1016\/J.TCM.2012.07.003","journal-title":"Trends Cardiovasc Med"},{"key":"1059_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/S43018-023-00704-X","author":"M Rogava","year":"2024","unstructured":"Rogava M, Aprati TJ, Chi WY, Melms JC, Hug C, Davis SH, Earlie EM, Chung C, Deshmukh SK, Wu S, Sledge G, Tang S, Ho P, Amin AD, Caprio L, Gurjao C, Tagore S, Ngo B, Lee MJ, Zanetti G, Wang Y, Chen S, Ge W, Melo LMN, Allies G, R\u00f6sler J, Gibney GT, Schmitz OJ, Sykes M, Creusot RJ, T\u00fcting T, Schadendorf D, R\u00f6cken M, Eigentler TK, Molotkov A, Mintz A, Bakhoum SF, Beyaz S, Cantley LC, Sorger PK, Meckelmann SW, Tasdogan A, Liu D, Laughney AM, Izar B (2024) Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation. Nat Cancer. https:\/\/doi.org\/10.1038\/S43018-023-00704-X","journal-title":"Nat Cancer"},{"key":"1059_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2021.725465","author":"G Rokszin","year":"2021","unstructured":"Rokszin G, Kiss Z, S\u00fct\u0151 G, Kempler P, Jermendy G, F\u00e1bi\u00e1n I, Szekanecz Z, Po\u00f3r G, Wittmann I, Moln\u00e1r GA (2021) Sodium\u2013glucose co-transporter 2 inhibitors may change the development of urinary tract and hematological malignancies as compared with dipeptidyl peptidase-4 inhibitors: data of the post-hoc analysis of a nationwide study. Front Oncol. https:\/\/doi.org\/10.3389\/FONC.2021.725465","journal-title":"Front Oncol"},{"key":"1059_CR120","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-023-07517-1","author":"M Ryaboshapkina","year":"2023","unstructured":"Ryaboshapkina M, Ye R, Ye Y, Birnbaum Y (2023) Effects of dapagliflozin on myocardial gene expression in btbr mice with type 2 diabetes. Cardiovasc Drugs Ther. https:\/\/doi.org\/10.1007\/s10557-023-07517-1","journal-title":"Cardiovasc Drugs Ther"},{"key":"1059_CR121","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/S12933-020-01040-5","volume":"19","author":"J Sabatino","year":"2020","unstructured":"Sabatino J, De Rosa S, Tamm\u00e8 L, Iaconetti C, Sorrentino S, Polimeni A, Mignogna C, Amorosi A, Spaccarotella C, Yasuda M, Indolfi C (2020) Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovasc Diabetol 19:66. https:\/\/doi.org\/10.1186\/S12933-020-01040-5","journal-title":"Cardiovasc Diabetol"},{"key":"1059_CR122","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/J.JACCAO.2023.08.003","volume":"5","author":"FN Salloum","year":"2023","unstructured":"Salloum FN, Tocchetti CG, Ameri P, Ardehali H, Asnani A, de Boer RA, Burridge P, Cabrera J\u00c1, de Castro J, C\u00f3rdoba R, Costa A, Dent S, Engelbertsen D, Fern\u00e1ndez-Velasco M, Fradley M, Fuster JJ, Gal\u00e1n-Arriola C, Garc\u00eda-Lunar I, Ghigo A, Gonz\u00e1lez-Neira A, Hirsch E, Ib\u00e1\u00f1ez B, Kitsis RN, Konety S, Lyon AR, Martin P, Mauro AG, Mazo Vega MM, Meijers WC, Neilan TG, Rassaf T, Ricke-Hoch M, Sepulveda P, Thavendiranathan P, van der Meer P, Fuster V, Ky B, L\u00f3pez-Fern\u00e1ndez T (2023) Priorities in cardio-oncology basic and translational science: GCOS 2023 symposium proceedings: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 5:715\u2013731. https:\/\/doi.org\/10.1016\/J.JACCAO.2023.08.003","journal-title":"JACC CardioOncol"},{"key":"1059_CR123","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/J.BBRC.2015.12.051","volume":"469","author":"GE Sandanger","year":"2016","unstructured":"Sandanger GE, Ranheim T, Bliks\u00f8en M, Kaasb\u00f8ll OJ, Alfsnes K, Nymo SH, Rashidi A, Ohm IK, Attramadal H, Aukrust P, Vinge LE, Yndestad A (2016) NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective. Biochem Biophys Res Commun 469:1012\u20131020. https:\/\/doi.org\/10.1016\/J.BBRC.2015.12.051","journal-title":"Biochem Biophys Res Commun"},{"key":"1059_CR124","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","volume":"139","author":"M Sano","year":"2019","unstructured":"Sano M, Goto S (2019) Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 139:1985\u20131987. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038881","journal-title":"Circulation"},{"key":"1059_CR125","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/NEJMCIBR1214975\/SUPPL_FILE\/NEJMCIBR1214975_DISCLOSURES.PDF","volume":"368","author":"DB Sawyer","year":"2013","unstructured":"Sawyer DB (2013) Anthracyclines and heart failure. N Engl J Med 368:1154\u20131156. https:\/\/doi.org\/10.1056\/NEJMCIBR1214975\/SUPPL_FILE\/NEJMCIBR1214975_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"key":"1059_CR126","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/01.RES.84.3.257","volume":"84","author":"DB Sawyer","year":"1999","unstructured":"Sawyer DB, Fukazawa R, Arstall MA, Kelly RA (1999) Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 84:257\u2013265. https:\/\/doi.org\/10.1161\/01.RES.84.3.257","journal-title":"Circ Res"},{"key":"1059_CR127","doi-asserted-by":"publisher","first-page":"E4111","DOI":"10.1073\/PNAS.1511698112","volume":"112","author":"C Scafoglio","year":"2015","unstructured":"Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N, Moatamed NA, Huang J, Koepsell H, Barrio JR, Wright EM (2015) Functional expression of sodium\u2013glucose transporters in cancer. Proc Natl Acad Sci U S A 112:E4111\u2013E4119. https:\/\/doi.org\/10.1073\/PNAS.1511698112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1059_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/FCVM.2022.1008922","author":"L Scisciola","year":"2022","unstructured":"Scisciola L, Cataldo V, Taktaz F, Fontanella RA, Pesapane A, Ghosh P, Franzese M, Puocci A, De Angelis A, Sportiello L, Marfella R, Barbieri M (2022) Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/FCVM.2022.1008922","journal-title":"Front Cardiovasc Med"},{"key":"1059_CR129","doi-asserted-by":"publisher","DOI":"10.1007\/S11864-020-0719-1","author":"T Shiga","year":"2020","unstructured":"Shiga T, Hiraide M (2020) Cardiotoxicities of 5-fluorouracil and other fluoropyrimidines. Curr Treat Options Oncol. https:\/\/doi.org\/10.1007\/S11864-020-0719-1","journal-title":"Curr Treat Options Oncol"},{"key":"1059_CR130","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMOA2206286\/SUPPL_FILE\/NEJMOA2206286_DATA-SHARING.PDF","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang C-E, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O\u2019Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilder\u00e4ng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMOA2206286\/SUPPL_FILE\/NEJMOA2206286_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"key":"1059_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/IJMM.2021.5072\/HTML","volume":"49","author":"L Sun","year":"2022","unstructured":"Sun L, Wang H, Yu S, Zhang L, Jiang J, Zhou Q (2022) Herceptin induces ferroptosis and mitochondrial dysfunction in H9c2 cells. Int J Mol Med 49:1\u20138. https:\/\/doi.org\/10.3892\/IJMM.2021.5072\/HTML","journal-title":"Int J Mol Med"},{"key":"1059_CR132","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1042\/CS20190863","volume":"133","author":"MT Swe","year":"2019","unstructured":"Swe MT, Thongnak L, Jaikumkao K, Pongchaidecha A, Chatsudthipong V, Lungkaphin A (2019) Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats. Clin Sci 133:2415\u20132430. https:\/\/doi.org\/10.1042\/CS20190863","journal-title":"Clin Sci"},{"key":"1059_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/METABO11020087","volume":"11","author":"Z Szekeres","year":"2021","unstructured":"Szekeres Z, Toth K, Szabados E (2021) The effects of SGLT2 inhibitors on lipid metabolism. Metabolites 11:1\u20139. https:\/\/doi.org\/10.3390\/METABO11020087","journal-title":"Metabolites"},{"key":"1059_CR134","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/CPHY.C140059","volume":"5","author":"TC Tan","year":"2015","unstructured":"Tan TC, Neilan TG, Francis S, Plana JC, Scherrer-Crosbie M (2015) Anthracycline-induced cardiomyopathy in adults. Compr Physiol 5:1517\u20131540. https:\/\/doi.org\/10.1002\/CPHY.C140059","journal-title":"Compr Physiol"},{"key":"1059_CR135","doi-asserted-by":"publisher","first-page":"9182","DOI":"10.1016\/S0021-9258(17)47282-6","volume":"259","author":"KM Tewey","year":"1984","unstructured":"Tewey KM, Chenb GL, Nelsonf EM, Lius LF (1984) Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase 11. J Biol Chem 259:9182\u20139187. https:\/\/doi.org\/10.1016\/S0021-9258(17)47282-6","journal-title":"J Biol Chem"},{"key":"1059_CR136","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3109\/10428194.2013.802314","volume":"55","author":"MC Tisi","year":"2014","unstructured":"Tisi MC, Bozzoli V, Giachelia M, Massini G, Ricerca BM, Maiolo E, D\u2019Alo F, Larocca LM, Piciocchi A, Tjalsma H, Swinkels DW, Voso MT, Leone G, Hohaus S (2014) Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. Leuk Lymphoma 55:270\u2013275. https:\/\/doi.org\/10.3109\/10428194.2013.802314","journal-title":"Leuk Lymphoma"},{"key":"1059_CR137","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/J.YJMCC.2006.06.009","volume":"41","author":"M Tokarska-Schlattner","year":"2006","unstructured":"Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U (2006) New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41:389\u2013405. https:\/\/doi.org\/10.1016\/J.YJMCC.2006.06.009","journal-title":"J Mol Cell Cardiol"},{"key":"1059_CR138","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijcard.2019.01.038","volume":"280","author":"M Totzeck","year":"2019","unstructured":"Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T (2019) Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol 280:163\u2013175. https:\/\/doi.org\/10.1016\/j.ijcard.2019.01.038","journal-title":"Int J Cardiol"},{"key":"1059_CR139","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/OXFORDJOURNALS.JBCHEM.A003196","volume":"132","author":"T Tsuchiya","year":"2002","unstructured":"Tsuchiya T, Kominato Y, Ueda M (2002) Human hypoxic signal transduction through a signature motif in hepatocyte nuclear factor 4. J Biochem 132:37\u201344. https:\/\/doi.org\/10.1093\/OXFORDJOURNALS.JBCHEM.A003196","journal-title":"J Biochem"},{"key":"1059_CR140","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1126\/SCIENCE.1260419\/SUPPL_FILE\/1260419_UHLEN.SM.PDF","volume":"1979","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M, Fagerberg L, Hallstr\u00f6m BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson \u00c5, Kampf C, Sj\u00f6stedt E, Asplund A, Olsson IM, Edlund K, Lundberg E, Navani S, Szigyarto CAK, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, Von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, Von Heijne G, Nielsen J, Pont\u00e9n F (2015) Tissue-based map of the human proteome. Science 1979:347. https:\/\/doi.org\/10.1126\/SCIENCE.1260419\/SUPPL_FILE\/1260419_UHLEN.SM.PDF","journal-title":"Science"},{"key":"1059_CR141","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/S00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, Zuurbier CJ (2018) Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia 61:722\u2013726. https:\/\/doi.org\/10.1007\/S00125-017-4509-7","journal-title":"Diabetologia"},{"key":"1059_CR142","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/S10557-020-07083-W","volume":"35","author":"L Uthman","year":"2021","unstructured":"Uthman L, Kuschma M, R\u00f6mer G, Boomsma M, Kessler J, Hermanides J, Hollmann MW, Preckel B, Zuurbier CJ, Weber NC (2021) Novel anti-inflammatory effects of canagliflozin involving hexokinase ii in lipopolysaccharide-stimulated human coronary artery endothelial cells. Cardiovasc Drugs Ther 35:1083\u20131094. https:\/\/doi.org\/10.1007\/S10557-020-07083-W","journal-title":"Cardiovasc Drugs Ther"},{"key":"1059_CR143","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/S00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC (2017) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60:215\u2013225. https:\/\/doi.org\/10.1007\/S00125-016-4157-3","journal-title":"Diabetologia"},{"key":"1059_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2023.115686","volume":"168","author":"Z Vaziri","year":"2023","unstructured":"Vaziri Z, Saleki K, Aram C, Alijanizadeh P, Pourahmad R, Azadmehr A, Ziaei N (2023) Empagliflozin treatment of cardiotoxicity: a comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications. Biomed Pharmacother 168:115686. https:\/\/doi.org\/10.1016\/J.BIOPHA.2023.115686","journal-title":"Biomed Pharmacother"},{"key":"1059_CR145","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/CLPT.2013.201","volume":"95","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh ETH (2014) Topoisomerase 2\u03b2: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther 95:45\u201352. https:\/\/doi.org\/10.1038\/CLPT.2013.201","journal-title":"Clin Pharmacol Ther"},{"key":"1059_CR146","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/ARS.2011.4373","volume":"18","author":"C Villeneuve","year":"2012","unstructured":"Villeneuve C, Guilbeau-Frugier C, Sicard P, Lairez O, Ordener C, Duparc T, De Paulis D, Couderc B, Spreux-Varoquaux O, Tortosa F, Garnier A, Knauf C, Valet P, Borchi E, Nediani C, Gharib A, Ovize M, Delisle MB, Parini A, Mialet-Perez J (2012) p53-PGC-1\u03b1 pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-A upregulation: role in chronic left ventricular dysfunction in mice. Antioxid Redox Signal 18:5\u201318. https:\/\/doi.org\/10.1089\/ARS.2011.4373","journal-title":"Antioxid Redox Signal"},{"key":"1059_CR147","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMRA041809","volume":"352","author":"G Weiss","year":"2005","unstructured":"Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352:1011\u20131023. https:\/\/doi.org\/10.1056\/NEJMRA041809","journal-title":"N Engl J Med"},{"key":"1059_CR148","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/S00424-020-02448-4","volume":"472","author":"EM Wright","year":"2020","unstructured":"Wright EM (2020) SGLT2 and cancer. Pflugers Arch 472:1407\u20131414. https:\/\/doi.org\/10.1007\/S00424-020-02448-4","journal-title":"Pflugers Arch"},{"key":"1059_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/S41419-022-04980-W","author":"W Wu","year":"2022","unstructured":"Wu W, Zhang Z, Jing D, Huang X, Ren D, Shao Z, Zhang Z (2022) SGLT2 inhibitor activates the STING\/IRF3\/IFN-\u03b2 pathway and induces immune infiltration in osteosarcoma. Cell Death Dis. https:\/\/doi.org\/10.1038\/S41419-022-04980-W","journal-title":"Cell Death Dis"},{"key":"1059_CR150","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/J.CSBJ.2019.03.006","volume":"17","author":"X Wu","year":"2019","unstructured":"Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, Liu X (2019) Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J 17:661\u2013674. https:\/\/doi.org\/10.1016\/J.CSBJ.2019.03.006","journal-title":"Comput Struct Biotechnol J"},{"key":"1059_CR151","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/J.CANLET.2020.09.005","volume":"495","author":"Z Xie","year":"2020","unstructured":"Xie Z, Wang F, Lin L, Duan S, Liu X, Li X, Li T, Xue M, Cheng Y, Ren H, Zhu Y (2020) An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells. Cancer Lett 495:200\u2013210. https:\/\/doi.org\/10.1016\/J.CANLET.2020.09.005","journal-title":"Cancer Lett"},{"key":"1059_CR152","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/J.BCP.2018.03.013","volume":"152","author":"C Xu","year":"2018","unstructured":"Xu C, Wang W, Zhong J, Lei F, Xu N, Zhang Y, Xie W (2018) Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. Biochem Pharmacol 152:45\u201359. https:\/\/doi.org\/10.1016\/J.BCP.2018.03.013","journal-title":"Biochem Pharmacol"},{"key":"1059_CR153","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/S13340-020-00474-2\/FIGURES\/5","volume":"12","author":"T Yamada","year":"2021","unstructured":"Yamada T, Sakaguchi K, Okada Y, Miura H, Otowa-Suematsu N, So A, Komada H, Hirota Y, Ohara T, Kuroki Y, Hara K, Matsuda T, Kishi M, Takeda A, Yokota K, Tamori Y, Ogawa W (2021) Analysis of time-dependent alterations of parameters related to erythrocytes after ipragliflozin initiation. Diabetol Int 12:197\u2013206. https:\/\/doi.org\/10.1007\/S13340-020-00474-2\/FIGURES\/5","journal-title":"Diabetol Int"},{"key":"1059_CR154","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, Sriramaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, Stockwell BR (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156:317\u2013331. https:\/\/doi.org\/10.1016\/j.cell.2013.12.010","journal-title":"Cell"},{"key":"1059_CR155","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1002\/JCP.26760","volume":"234","author":"H Yaribeygi","year":"2019","unstructured":"Yaribeygi H, Atkin SL, Butler AE, Sahebkar A (2019) Sodium\u2013glucose cotransporter inhibitors and oxidative stress: an update. J Cell Physiol 234:3231\u20133237. https:\/\/doi.org\/10.1002\/JCP.26760","journal-title":"J Cell Physiol"},{"key":"1059_CR156","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1002\/JCP.30851","volume":"237","author":"H Yaribeygi","year":"2022","unstructured":"Yaribeygi H, Maleki M, Nasimi F, Butler AE, Jamialahmadi T, Sahebkar A (2022) Sodium\u2013glucose co-transporter 2 inhibitors and hematopoiesis. J Cell Physiol 237:3778\u20133787. https:\/\/doi.org\/10.1002\/JCP.30851","journal-title":"J Cell Physiol"},{"key":"1059_CR157","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/J.EBIOM.2018.06.009","volume":"35","author":"J Ye","year":"2018","unstructured":"Ye J, Huang Y, Que B, Chang C, Liu W, Hu H, Liu L, Shi Y, Wang Y, Wang M, Zeng T, Zhen W, Xu Y, Shi L, Liu J, Jiang H, Ye D, Lin Y, Wan J, Ji Q (2018) Interleukin-12p35 knock out aggravates doxorubicin-induced cardiac injury and dysfunction by aggravating the inflammatory response, oxidative stress, apoptosis and autophagy in mice. EBioMedicine 35:29\u201339. https:\/\/doi.org\/10.1016\/J.EBIOM.2018.06.009","journal-title":"EBioMedicine"},{"key":"1059_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/J.REDOX.2020.101636","volume":"36","author":"J Ye","year":"2020","unstructured":"Ye J, Wang Y, Xu Y, Wang Z, Liu L, Wang M, Ye D, Zhang J, Yang Z, Lin Y, Ji Q, Wan J (2020) Interleukin-22 deficiency alleviates doxorubicin-induced oxidative stress and cardiac injury via the p38 MAPK\/macrophage\/Fizz3 axis in mice. Redox Biol 36:101636. https:\/\/doi.org\/10.1016\/J.REDOX.2020.101636","journal-title":"Redox Biol"},{"key":"1059_CR159","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1172\/JCI118909","volume":"98","author":"HC Yen","year":"1996","unstructured":"Yen HC, Oberley TD, Vichitbandha S, Ho YS, St. Clair DK (1996) The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 98:1253\u20131260. https:\/\/doi.org\/10.1172\/JCI118909","journal-title":"J Clin Invest"},{"key":"1059_CR160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.TIV.2018.05.001","volume":"51","author":"J Yin","year":"2018","unstructured":"Yin J, Guo J, Zhang Q, Cui L, Zhang L, Zhang T, Zhao J, Li J, Middleton A, Carmichael PL, Peng S (2018) Doxorubicin-induced mitophagy and mitochondrial damage is associated with dysregulation of the PINK1\/parkin pathway. Toxicol In Vitro 51:1\u201310. https:\/\/doi.org\/10.1016\/J.TIV.2018.05.001","journal-title":"Toxicol In Vitro"},{"key":"1059_CR161","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/EJHF.1473","volume":"21","author":"SR Yurista","year":"2019","unstructured":"Yurista SR, Sillj\u00e9 HHW, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, van Goor H, van Veldhuisen DJ, de Boer RA, Westenbrink BD (2019) Sodium\u2013glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail 21:862\u2013873. https:\/\/doi.org\/10.1002\/EJHF.1473","journal-title":"Eur J Heart Fail"},{"key":"1059_CR162","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. The Lancet 396:819\u2013829. https:\/\/doi.org\/10.1016\/S0140-6736(20)31824-9","journal-title":"The Lancet"},{"key":"1059_CR163","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD (2020) Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation 141:1227\u20131234. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044183","journal-title":"Circulation"},{"key":"1059_CR164","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/J.JACC.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E (2020) Mechanisms of cardiorenal effects of sodium\u2013glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 75:422\u2013434. https:\/\/doi.org\/10.1016\/J.JACC.2019.11.031","journal-title":"J Am Coll Cardiol"},{"key":"1059_CR165","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/J.KINT.2018.05.002","volume":"94","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Nakano D, Guan Y, Hitomi H, Uemura A, Masaki T, Kobara H, Sugaya T, Nishiyama A (2018) A sodium\u2013glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int 94:524\u2013535. https:\/\/doi.org\/10.1016\/J.KINT.2018.05.002","journal-title":"Kidney Int"},{"key":"1059_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2023.111151","volume":"125","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhang D, Meng T, Tian P, Chen J, Liu A, Zheng Y, Su G (2023) SGK1 is involved in doxorubicin-induced chronic cardiotoxicity and dysfunction through activation of the NF\u03baB pathway. Int Immunopharmacol 125:111151. https:\/\/doi.org\/10.1016\/J.INTIMP.2023.111151","journal-title":"Int Immunopharmacol"},{"key":"1059_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-023-01483-1","volume":"9","author":"J Zhao","year":"2023","unstructured":"Zhao J, Zhang N, Ma X, Li M, Feng H (2023) The dual role of ferroptosis in anthracycline-based chemotherapy includes reducing resistance and increasing toxicity. Cell Death Discov 9:1\u201312. https:\/\/doi.org\/10.1038\/s41420-023-01483-1","journal-title":"Cell Death Discov"},{"key":"1059_CR168","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2217\/IMT-2018-0214","volume":"11","author":"L Zhao","year":"2019","unstructured":"Zhao L, Yang Y, Gao Q (2019) Efficacy and safety of nivolumab plus apatinib in advanced liver carcinosarcoma: a case report. Immunotherapy 11:651\u2013656. https:\/\/doi.org\/10.2217\/IMT-2018-0214","journal-title":"Immunotherapy"},{"key":"1059_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2020.110821","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhu J, Yu SJ, Ma HL, Chen J, Ding XF, Chen G, Liang Y, Zhang Q (2020) Sodium\u2013glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway. Biomed Pharmacother. https:\/\/doi.org\/10.1016\/J.BIOPHA.2020.110821","journal-title":"Biomed Pharmacother"},{"key":"1059_CR170","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"1059_CR171","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/J.JACCAO.2022.03.005","volume":"4","author":"LL Zullig","year":"2022","unstructured":"Zullig LL, Sung AD, Khouri MG, Jazowski S, Shah NP, Sitlinger A, Blalock DV, Whitney C, Kikuchi R, Bosworth HB, Crowley MJ, Goldstein KM, Klem I, Oeffinger KC, Dent S (2022) Cardiometabolic comorbidities in cancer survivors: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 4:149\u2013165. https:\/\/doi.org\/10.1016\/J.JACCAO.2022.03.005","journal-title":"JACC CardioOncol"}],"container-title":["Basic Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00395-024-01059-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00395-024-01059-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00395-024-01059-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T14:08:12Z","timestamp":1738591692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00395-024-01059-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":171,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["1059"],"URL":"https:\/\/doi.org\/10.1007\/s00395-024-01059-9","relation":{},"ISSN":["1435-1803"],"issn-type":[{"value":"1435-1803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}